Combination Therapies for the Treatment of Alzheimer's Disease and Related Disorders

Abstract

The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.

1 - 20 . (canceled) 
     
     
         21 . A method of treating a disease or condition in a subject in need thereof comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound, wherein the disease or condition is Alzheimer's disease, dementia, an amyloidosis-associated condition, or a head injury. 
     
     
         22 . A method of slowing the progression of a disease or condition in a subject in need thereof comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound, wherein the disease or condition is Alzheimer's disease, dementia, an amyloidosis-associated condition, or a head injury. 
     
     
         23 . The method of  claim 21 , wherein the first compound and the second compound regulate amyloid peptide washout. 
     
     
         24 . The method of  claim 22 , wherein the first compound and the second compound regulate amyloid peptide washout. 
     
     
         25 . The method of  claim 23 , wherein the compounds that regulate amyloid peptide washout are Aβ peptide specific antibodies. 
     
     
         26 . The method of  claim 25 , wherein the Aβ peptide specific antibodies are selected from the group consisting of bapineuzumab, solanezumab, gammaglobulin IV, and PF-4360365. 
     
     
         27 . The method of  claim 23 , wherein the compounds that regulate amyloid peptide washout are anti-beta amyloid vaccines. 
     
     
         28 . The method of  claim 27 , wherein the anti-beta amyloid vaccines are ACC-001 (Elan/Johnson & Johnson). 
     
     
         29 . The method of  claim 23 , wherein the compounds that regulate amyloid peptide washout are siRNAs that target Aβ peptide. 
     
     
         30 . The method of  claim 23 , wherein the compounds that regulate amyloid peptide washout are nerve growth factor (NGF) gene therapy. 
     
     
         31 . The method of  claim 30 , wherein the nerve growth factor (NGF) gene therapy is CERE-110 (Ceregene Inc.). 
     
     
         32 . The method of  claim 23 , wherein the compounds that regulate amyloid peptide washout are gamma-secretase inhibitors. 
     
     
         33 . The method of  claim 32 , wherein the gamma-secretase inhibitors are either Semagacestat (LY450139) or NIC5-15 (Humanetics). 
     
     
         34 . The method of  claim 24 , wherein the compounds that regulate amyloid peptide washout are Aβ peptide specific antibodies. 
     
     
         35 . The method of  claim 34 , wherein the Aβ peptide specific antibodies are selected from the group consisting of bapineuzumab, solanezumab, gammaglobulin IV, and PF-4360365. 
     
     
         36 . The method of  claim 24 , wherein the compounds that regulate amyloid peptide washout are anti-beta amyloid vaccines. 
     
     
         37 . The method of  claim 36 , wherein the anti-beta amyloid vaccines are ACC-001 (Elan/Johnson & Johnson). 
     
     
         38 . The method of  claim 24 , wherein the compounds that regulate amyloid peptide washout are siRNAs that target Aβ peptide. 
     
     
         39 . The method of  claim 24 , wherein the compounds that regulate amyloid peptide washout are nerve growth factor (NGF) gene therapy. 
     
     
         40 . The method of  claim 39 , wherein the nerve growth factor (NGF) gene therapy is CERE-110 (Ceregene Inc.). 
     
     
         41 . The method of  claim 24 , wherein the compounds that regulate amyloid peptide washout are gamma-secretase inhibitors. 
     
     
         42 . The method of  claim 41 , wherein the gamma-secretase inhibitors are either Semagacestat (LY450139) or NIC5-15 (Humanetics).